DrugBiological
Anetumab ravtansine clinical trials
Also written BAY 94-9343.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 5
Bayer (7) · National Cancer Institute (NCI) (3) · Yale University (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Paclitaxel (1) · Itraconazole (1) · Liposomal doxorubicin (1) · Doxorubicin (1) · Atezolizumab (1)
Studies
Open first, then newest update. How each study uses anetumab ravtansine is read from its arms, and is right about nine times in ten.
Testing it · 12
- Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural MesotheliomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT03126630Written as Anetumab Ravtansine
- Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03587311Written as Anetumab Ravtansine
- A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine StudiesTerminatedPhase 2BayerNCT03926143Written as BAY94-9343 (Anetumab ravtansine)
- Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung CancerTerminatedPhase 1Mayo ClinicNCT03455556Written as Anetumab Ravtansine
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic CancerCompletedPhase 2Yale UniversityNCT03023722Written as anetumab ravtansine
- Phase I Study of Anetumab Ravtansine in Hepatic or Renal ImpairmentCompletedPhase 1BayerNCT02696642Written as Anetumab ravtansine (BAY94-9343)
- Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.CompletedPhase 1BayerNCT01439152Written as BAY94-9343
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)CompletedPhase 2BayerNCT02610140Written as Anetumab ravtansine (BAY94-9343)
- Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and ItraconazoleCompletedPhase 1BayerNCT02824042Written as Anetumab ravtansine (BAY94-9343)
- Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant CancerCompletedPhase 1BayerNCT02751918Written as Anetumab ravtansine (BAY94-9343)
- Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaTerminatedPhase 2National Cancer Institute (NCI)NCT02839681Written as Anetumab Ravtansine
- Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced MalignanciesCompletedPhase 1BayerNCT02485119Written as BAY94-9343
Given in every arm · 3 — anetumab ravtansine is usual care beside what is tested
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT03816358Written as Anetumab Ravtansine
- Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsCompletedPhase 1BayerNCT03102320Written as Anetumab ravtansine (BAY94-9343)
- Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid TumorsCompletedPhase 1BayerNCT02639091Written as BAY 94-9343
Codes
What other systems call anetumab ravtansine · ClinicalTrials.gg INT000174
- MeSH (NLM) C000595240anetumab ravtansineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) M170940PMIANETUMAB RAVTANSINEConfirmed FDA, NLM, Wikidata
- Wikidata Q101011513anetumab ravtansineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98293Anetumab RavtansineOne source FDA
- DrugBank DB14809One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595240 | anetumab ravtansine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | M170940PMI | ANETUMAB RAVTANSINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q101011513 | anetumab ravtansine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98293 | Anetumab Ravtansine | One source FDA |
| DrugBank | DB14809 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.